Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (NYSE:BMY)

Analysis of Profitability Ratios

Beginner level

Profitability Ratios (Summary)

Bristol-Myers Squibb Co., profitability ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Return on Sales
Gross profit margin 72.31% 69.10% 70.98% 70.80% 74.54%
Operating profit margin -21.60% 22.62% 22.69% 17.39% 23.83%
Net profit margin -21.20% 13.15% 21.81% 4.85% 22.94%
Return on Investment
Return on equity (ROE) -23.84% 6.66% 35.07% 8.58% 27.55%
Return on assets (ROA) -7.61% 2.65% 14.06% 3.00% 13.22%

Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Bristol-Myers Squibb Co.’s gross profit margin ratio deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Bristol-Myers Squibb Co.’s operating profit margin ratio deteriorated from 2018 to 2019 and from 2019 to 2020.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Bristol-Myers Squibb Co.’s net profit margin ratio deteriorated from 2018 to 2019 and from 2019 to 2020.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Bristol-Myers Squibb Co.’s ROE deteriorated from 2018 to 2019 and from 2019 to 2020.
ROA A profitability ratio calculated as net income divided by total assets. Bristol-Myers Squibb Co.’s ROA deteriorated from 2018 to 2019 and from 2019 to 2020.

Gross Profit Margin

Bristol-Myers Squibb Co., gross profit margin calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Gross margin 30,745  18,067  16,014  14,710  14,481 
Revenues 42,518  26,145  22,561  20,776  19,427 
Profitability Ratio
Gross profit margin1 72.31% 69.10% 70.98% 70.80% 74.54%
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 50.49% 52.46% 51.32% 47.75% 54.09%
AbbVie Inc. 66.41% 77.64% 76.44% 75.05% 77.25%
Amgen Inc. 74.59% 80.38% 81.80% 81.33% 80.99%
Eli Lilly & Co. 77.66% 78.85% 73.81% 73.46% 73.35%
Gilead Sciences Inc. 78.86% 77.61% 82.97% 85.77%
Illumina Inc. 68.01% 69.63% 69.01% 66.35% 69.48%
Johnson & Johnson 65.58% 66.42% 66.79% 66.84% 69.84%
Merck & Co. Inc. 69.87% 68.06% 68.16% 65.10%
Pfizer Inc. 80.25% 79.03% 78.61% 76.66%
Regeneron Pharmaceuticals Inc. 86.82% 90.05% 93.53% 93.24% 93.83%
Vertex Pharmaceuticals Inc. 88.14% 86.84% 86.56% 88.95% 87.64%
Zoetis Inc. 69.18% 68.18% 67.19% 66.55% 65.92%

Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).

1 2020 Calculation
Gross profit margin = 100 × Gross margin ÷ Revenues
= 100 × 30,745 ÷ 42,518 = 72.31%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Bristol-Myers Squibb Co.’s gross profit margin ratio deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level.

Operating Profit Margin

Bristol-Myers Squibb Co., operating profit margin calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Operating income (loss) (9,185) 5,913  5,118  3,612  4,630 
Revenues 42,518  26,145  22,561  20,776  19,427 
Profitability Ratio
Operating profit margin1 -21.60% 22.62% 22.69% 17.39% 23.83%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 15.48% 14.21% 11.94% 6.30% 15.27%
AbbVie Inc. 24.81% 39.03% 19.49% 33.99% 36.60%
Amgen Inc. 37.70% 43.57% 45.55% 45.76% 44.74%
Eli Lilly & Co. 24.69% 22.29% 15.15% 9.38% 16.30%
Gilead Sciences Inc. 19.38% 37.83% 55.04% 58.87%
Illumina Inc. 17.91% 27.80% 26.49% 22.02% 24.48%
Johnson & Johnson 23.60% 24.15% 24.27% 24.07% 28.72%
Merck & Co. Inc. 24.77% 19.62% 16.28% 13.51%
Pfizer Inc. 25.46% 26.10% 25.92% 22.73%
Regeneron Pharmaceuticals Inc. 42.09% 28.10% 37.77% 35.41% 27.38%
Vertex Pharmaceuticals Inc. 46.03% 28.77% 20.84% 4.95% 0.58%
Zoetis Inc. 33.62% 31.42% 31.12% 32.15% 28.48%
Operating Profit Margin, Sector
Pharmaceuticals & Biotechnology 25.89% 24.29% 25.36% 28.18%
Operating Profit Margin, Industry
Health Care 18.67% 17.79% 18.39% 19.66%

Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).

1 2020 Calculation
Operating profit margin = 100 × Operating income (loss) ÷ Revenues
= 100 × -9,185 ÷ 42,518 = -21.60%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Bristol-Myers Squibb Co.’s operating profit margin ratio deteriorated from 2018 to 2019 and from 2019 to 2020.

Net Profit Margin

Bristol-Myers Squibb Co., net profit margin calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS (9,015) 3,439  4,920  1,007  4,457 
Revenues 42,518  26,145  22,561  20,776  19,427 
Profitability Ratio
Net profit margin1 -21.20% 13.15% 21.81% 4.85% 22.94%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 12.99% 11.56% 7.74% 1.74% 6.71%
AbbVie Inc. 10.08% 23.69% 17.36% 18.82% 23.22%
Amgen Inc. 29.97% 35.32% 37.25% 9.08% 35.27%
Eli Lilly & Co. 25.24% 37.27% 13.16% -0.89% 12.90%
Gilead Sciences Inc. 24.35% 25.16% 18.03% 45.07%
Illumina Inc. 20.25% 28.28% 24.78% 26.38% 19.29%
Johnson & Johnson 17.82% 18.42% 18.75% 1.70% 23.01%
Merck & Co. Inc. 21.01% 14.71% 5.97% 9.85%
Pfizer Inc. 31.45% 20.79% 40.55% 13.66%
Regeneron Pharmaceuticals Inc. 41.35% 26.91% 36.42% 20.41% 18.42%
Vertex Pharmaceuticals Inc. 43.70% 28.27% 68.80% 10.59% -6.58%
Zoetis Inc. 24.54% 23.96% 24.52% 16.28% 16.80%
Net Profit Margin, Sector
Pharmaceuticals & Biotechnology 23.19% 19.80% 12.42% 20.64%
Net Profit Margin, Industry
Health Care 16.41% 14.00% 9.98% 14.08%

Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).

1 2020 Calculation
Net profit margin = 100 × Net earnings (loss) attributable to BMS ÷ Revenues
= 100 × -9,015 ÷ 42,518 = -21.20%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Bristol-Myers Squibb Co.’s net profit margin ratio deteriorated from 2018 to 2019 and from 2019 to 2020.

Return on Equity (ROE)

Bristol-Myers Squibb Co., ROE calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS (9,015) 3,439  4,920  1,007  4,457 
Total Bristol-Myers Squibb Company shareholders’ equity 37,822  51,598  14,031  11,741  16,177 
Profitability Ratio
ROE1 -23.84% 6.66% 35.07% 8.58% 27.55%
Benchmarks
ROE, Competitors2
Abbott Laboratories 13.71% 11.86% 7.76% 1.54% 6.82%
AbbVie Inc. 35.30% 104.16% 128.41%
Amgen Inc. 77.20% 81.07% 67.15% 7.84% 25.85%
Eli Lilly & Co. 109.79% 319.09% 32.88% -1.76% 19.54%
Gilead Sciences Inc. 23.91% 25.51% 22.64% 71.48%
Illumina Inc. 13.98% 21.72% 21.98% 26.41% 21.06%
Johnson & Johnson 23.25% 25.42% 25.60% 2.16% 23.49%
Merck & Co. Inc. 37.99% 23.30% 6.97% 9.78%
Pfizer Inc. 25.77% 17.59% 29.88% 12.12%
Regeneron Pharmaceuticals Inc. 31.86% 19.08% 27.91% 19.51% 20.13%
Vertex Pharmaceuticals Inc. 31.22% 19.34% 47.28% 12.99% -9.69%
Zoetis Inc. 43.46% 55.39% 65.35% 48.81% 55.21%
ROE, Sector
Pharmaceuticals & Biotechnology 29.60% 27.94% 14.55% 23.11%
ROE, Industry
Health Care 23.37% 21.29% 13.59% 18.84%

Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).

1 2020 Calculation
ROE = 100 × Net earnings (loss) attributable to BMS ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= 100 × -9,015 ÷ 37,822 = -23.84%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Bristol-Myers Squibb Co.’s ROE deteriorated from 2018 to 2019 and from 2019 to 2020.

Return on Assets (ROA)

Bristol-Myers Squibb Co., ROA calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Net earnings (loss) attributable to BMS (9,015) 3,439  4,920  1,007  4,457 
Total assets 118,481  129,944  34,986  33,551  33,707 
Profitability Ratio
ROA1 -7.61% 2.65% 14.06% 3.00% 13.22%
Benchmarks
ROA, Competitors2
Abbott Laboratories 6.20% 5.43% 3.53% 0.63% 2.66%
AbbVie Inc. 3.07% 8.84% 9.58% 7.50% 9.01%
Amgen Inc. 11.54% 13.13% 12.64% 2.48% 9.95%
Eli Lilly & Co. 13.28% 21.17% 7.36% -0.45% 7.05%
Gilead Sciences Inc. 8.74% 8.57% 6.58% 23.70%
Illumina Inc. 8.65% 13.70% 11.87% 13.81% 10.81%
Johnson & Johnson 8.41% 9.59% 10.00% 0.83% 11.71%
Merck & Co. Inc. 11.66% 7.53% 2.72% 4.11%
Pfizer Inc. 9.72% 7.00% 12.40% 4.20%
Regeneron Pharmaceuticals Inc. 20.47% 14.29% 20.83% 13.67% 12.84%
Vertex Pharmaceuticals Inc. 23.07% 14.15% 33.57% 7.43% -3.87%
Zoetis Inc. 12.04% 12.99% 13.25% 10.06% 10.73%
ROA, Sector
Pharmaceuticals & Biotechnology 9.30% 9.07% 5.04% 8.67%
ROA, Industry
Health Care 8.44% 7.94% 5.12% 7.42%

Based on: 10-K (filing date: 2021-02-10), 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21).

1 2020 Calculation
ROA = 100 × Net earnings (loss) attributable to BMS ÷ Total assets
= 100 × -9,015 ÷ 118,481 = -7.61%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Bristol-Myers Squibb Co.’s ROA deteriorated from 2018 to 2019 and from 2019 to 2020.